Celiac Disease - Pipeline Review, H2 2020
Celiac Disease - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2020, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 4, 1, 5 and 8 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2020, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 4, 1, 5 and 8 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Ahead Therapeutics SL
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Bioniz Therapeutics Inc
GlaxoSmithKline Plc
ImCyse SA
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Parvus Therapeutics Inc
Precigen Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
Celiac Disease - Drug Profiles
AG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HLA-DQ2 for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-5202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Discontinued Products
Celiac Disease - Product Development Milestones
Featured News & Press Releases
Sep 22, 2020: Beyond Celiac partners with Provention Bio on phase 2 clinical Trial for promising celiac disease therapeutic
Aug 31, 2020: Provention Bio announces initiation of phase 2b PROACTIVE study of PRV-015 (anti-IL-15) in non-responsive celiac disease
Jun 29, 2020: 9 Meters Biopharma amends definition of primary endpoint for phase 3 trial in celiac disease after consultation with FDA
May 11, 2020: 9 Meters Biopharma receives thorough QT study waiver by FDA for Larazotide being studied for celiac disease
Feb 27, 2020: Anokion announces initiation of patient dosing in Phase 1 clinical trial of KAN-101 in celiac disease
Feb 19, 2020: Innovate Biopharmaceuticals announces acceptance of three abstracts for the 2020 Digestive Disease Week (DDW) conference
Feb 14, 2020: ImmunogenX starts enrolment in Phase IIb celiac disease study
Jan 21, 2020: Anokion announces FDA clearance of IND application for its lead program in celiac disease
Oct 22, 2019: Takeda Pharmaceutical: New treatment may reverse celiac disease
Aug 19, 2019: ActoBio Therapeutics receives IND green light for new antigen-specific immunotherapy study aimed at improving celiac patients tolerance of gluten
Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
Jun 25, 2019: ImmusanT discontinues phase 2 clinical trial for Nexvax2 in patients with celiac disease
Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Ahead Therapeutics SL
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Bioniz Therapeutics Inc
GlaxoSmithKline Plc
ImCyse SA
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Parvus Therapeutics Inc
Precigen Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
Celiac Disease - Drug Profiles
AG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HLA-DQ2 for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-5202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Discontinued Products
Celiac Disease - Product Development Milestones
Featured News & Press Releases
Sep 22, 2020: Beyond Celiac partners with Provention Bio on phase 2 clinical Trial for promising celiac disease therapeutic
Aug 31, 2020: Provention Bio announces initiation of phase 2b PROACTIVE study of PRV-015 (anti-IL-15) in non-responsive celiac disease
Jun 29, 2020: 9 Meters Biopharma amends definition of primary endpoint for phase 3 trial in celiac disease after consultation with FDA
May 11, 2020: 9 Meters Biopharma receives thorough QT study waiver by FDA for Larazotide being studied for celiac disease
Feb 27, 2020: Anokion announces initiation of patient dosing in Phase 1 clinical trial of KAN-101 in celiac disease
Feb 19, 2020: Innovate Biopharmaceuticals announces acceptance of three abstracts for the 2020 Digestive Disease Week (DDW) conference
Feb 14, 2020: ImmunogenX starts enrolment in Phase IIb celiac disease study
Jan 21, 2020: Anokion announces FDA clearance of IND application for its lead program in celiac disease
Oct 22, 2019: Takeda Pharmaceutical: New treatment may reverse celiac disease
Aug 19, 2019: ActoBio Therapeutics receives IND green light for new antigen-specific immunotherapy study aimed at improving celiac patients tolerance of gluten
Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
Jun 25, 2019: ImmusanT discontinues phase 2 clinical trial for Nexvax2 in patients with celiac disease
Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Celiac Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Celiac Disease - Pipeline by 9 Meters Biopharma Inc, H2 2020
Celiac Disease - Pipeline by Ahead Therapeutics SL, H2 2020
Celiac Disease - Pipeline by Amgen Inc, H2 2020
Celiac Disease - Pipeline by Amyra Biotech AG, H2 2020
Celiac Disease - Pipeline by Anokion SA, H2 2020
Celiac Disease - Pipeline by AnTolRx Inc, H2 2020
Celiac Disease - Pipeline by Bioniz Therapeutics Inc, H2 2020
Celiac Disease - Pipeline by GlaxoSmithKline Plc, H2 2020
Celiac Disease - Pipeline by ImCyse SA, H2 2020
Celiac Disease - Pipeline by ImmunogenX LLC, H2 2020
Celiac Disease - Pipeline by ImmunoMolecular Therapeutics LLC, H2 2020
Celiac Disease - Pipeline by ImmusanT Inc, H2 2020
Celiac Disease - Pipeline by Parvus Therapeutics Inc, H2 2020
Celiac Disease - Pipeline by Precigen Inc, H2 2020
Celiac Disease - Pipeline by Protagonist Therapeutics Inc, H2 2020
Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Celiac Disease - Pipeline by Theravance Biopharma Inc, H2 2020
Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2020
Celiac Disease - Pipeline by Vactech Oy, H2 2020
Celiac Disease - Pipeline by Zedira GmbH, H2 2020
Celiac Disease - Dormant Projects, H2 2020
Celiac Disease - Dormant Projects, H2 2020 (Contd..1), H2 2020
Celiac Disease - Discontinued Products, H2 2020
Number of Products under Development for Celiac Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Celiac Disease - Pipeline by 9 Meters Biopharma Inc, H2 2020
Celiac Disease - Pipeline by Ahead Therapeutics SL, H2 2020
Celiac Disease - Pipeline by Amgen Inc, H2 2020
Celiac Disease - Pipeline by Amyra Biotech AG, H2 2020
Celiac Disease - Pipeline by Anokion SA, H2 2020
Celiac Disease - Pipeline by AnTolRx Inc, H2 2020
Celiac Disease - Pipeline by Bioniz Therapeutics Inc, H2 2020
Celiac Disease - Pipeline by GlaxoSmithKline Plc, H2 2020
Celiac Disease - Pipeline by ImCyse SA, H2 2020
Celiac Disease - Pipeline by ImmunogenX LLC, H2 2020
Celiac Disease - Pipeline by ImmunoMolecular Therapeutics LLC, H2 2020
Celiac Disease - Pipeline by ImmusanT Inc, H2 2020
Celiac Disease - Pipeline by Parvus Therapeutics Inc, H2 2020
Celiac Disease - Pipeline by Precigen Inc, H2 2020
Celiac Disease - Pipeline by Protagonist Therapeutics Inc, H2 2020
Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Celiac Disease - Pipeline by Theravance Biopharma Inc, H2 2020
Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2020
Celiac Disease - Pipeline by Vactech Oy, H2 2020
Celiac Disease - Pipeline by Zedira GmbH, H2 2020
Celiac Disease - Dormant Projects, H2 2020
Celiac Disease - Dormant Projects, H2 2020 (Contd..1), H2 2020
Celiac Disease - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Celiac Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
9 Meters Biopharma Inc
Ahead Therapeutics SL
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Bioniz Therapeutics Inc
GlaxoSmithKline Plc
ImCyse SA
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Parvus Therapeutics Inc
Precigen Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
Number of Products under Development for Celiac Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
9 Meters Biopharma Inc
Ahead Therapeutics SL
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Bioniz Therapeutics Inc
GlaxoSmithKline Plc
ImCyse SA
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Parvus Therapeutics Inc
Precigen Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
